Cognition Therapeutics Files 8-K

Ticker: CGTX · Form: 8-K · Filed: Aug 26, 2025 · CIK: 1455365

Cognition Therapeutics INC 8-K Filing Summary
FieldDetail
CompanyCognition Therapeutics INC (CGTX)
Form Type8-K
Filed DateAug 26, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001, $1.00 m, $1.00
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-filing

Related Tickers: COGT

TL;DR

COGT filed an 8-K, standard procedure, no major news yet.

AI Summary

Cognition Therapeutics, Inc. filed an 8-K on August 26, 2025, reporting an event under "Other Events." The filing does not contain specific details about the event itself, but it confirms the company's reporting status and basic corporate information.

Why It Matters

This filing indicates Cognition Therapeutics is fulfilling its regulatory reporting obligations, which is standard for publicly traded companies.

Risk Assessment

Risk Level: low — This is a routine filing with no new material information disclosed.

Key Numbers

Key Players & Entities

FAQ

What specific event is reported under "Other Events" in this 8-K filing?

The provided text for the 8-K filing does not specify the details of the event categorized under "Other Events."

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on August 26, 2025.

What is Cognition Therapeutics, Inc.'s state of incorporation?

Cognition Therapeutics, Inc. is incorporated in Delaware.

What is the company's principal executive office address?

The company's principal executive offices are located at 2500 Westchester Ave. Purchase, NY 10577.

What is the SEC file number for Cognition Therapeutics, Inc.?

The SEC file number for Cognition Therapeutics, Inc. is 001-40886.

Filing Stats: 480 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-08-26 16:01:49

Key Financial Figures

Filing Documents

01

Item 8.01 Other Events. As previously disclosed, on September 12, 2024, Cognition Therapeutics, Inc. (the "Company") received a deficiency letter from The Nasdaq Stock Market LLC ("Nasdaq") stating that the bid price of its common stock had closed below the $1.00 minimum required by Nasdaq Listing Rule 5450(a)(1) for the prior 30 consecutive trading days (the "Minimum Bid Price Requirement"). As of August 25, 2025, the Company's common stock had closed above $1.00 per share for more than ten consecutive trading days. As a result, on August 26, 2025, the Company received a letter from Nasdaq advising that the Company had regained compliance with the Minimum Bid Price Requirement and that the Company was therefore in compliance with Nasdaq's listing requirements.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. COGNITION THERAPEUTICS, INC. Date: August 26, 2025 By: /s/ Lisa Ricciardi Name: Lisa Ricciardi Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing